To validate the molecular binding capabilities of the three candidate drugs selected from DSigDB with the proteins encoded by the key genes related to Osteoporosis-stroke comorbidity (AGBL3, HNRNPL, LILRA5), to provide a structural basis for subsequent in vitro/in vivo functional validation and drug repositioning, molecular docking was performed on AGBL3, HNRNPL, and LILRA5 using AutoDock Vina. The gene discussed is HNRNPL; the disease is stroke disorder.